Michael Aguiar - Theravance Insider

Theravance Inc -- USA Stock  

USD 9.81  9.81  9,223,372,036,855%

CEO and President and Director

Mr. Michael W. Aguiar serves as President Chief Executive Officer Director of Theravance Inc. effective August 15 2014. He was appointed President and Chief Executive Officer of Innoviva Inc. and became a member of our Board of Directors in August 2014. He joined Innoviva as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Innoviva Mr. Aguiar served as Vice President of Finance at Gilead Sciences Inc. a biopharmaceutical company since 2002. Prior to Gilead Sciences Inc. Mr. Aguiar served as Vice President of Finance at Immunex Corporationrationration a biopharmaceutical company from 2001 to 2002. From 1995 to 2001 he was with Honeywell International in a variety of positions including most recently CFO and Vice President Finance for Honeywell Electronic Materials SBU. Mr. Aguiar earned a B.S. in biology from the University of California Irvine and an M.B.A. in finance from the University of Michigan. Mr. Aguiar demonstrated leadership in his field his prior senior management experience in our industry and his experience as our Chief Executive Officer and as our former Chief Financial Officer contributed to our conclusion that he should serve as a director.
Age: 48  CEO Since 2014  MBA    
650-238-9600  http://www.thrxinc.com
Aguiar earned a B.S. in Biology from UC Irvine and an M.B.A. in Finance from the University of Michigan.

Michael Aguiar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average.
The company currently holds 744.09 M in liabilities with Debt to Equity (D/E) ratio of 1.09 which is about average as compared to similar companies. Theravance Inc has Current Ratio of 19.44 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Theravance, Inc., a royalty management company, is focused on developing respiratory products. Theravance Inc (THRX) is traded on NASDAQ in USA. It is located in South San Francisco, CA and employs 13 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Theravance Inc to your portfolio

Top Management

Theravance Inc Leadership Team
Catherine Friedman, Director
Michael Aguiar, CEO, MBA
Barbara Duncan, Director
Paul Pepe, Director
George Abercrombie, President, MBA
Patrick LePore, Director
James Tyree, Director
Eric dEsparbes, CFO
Terrence Kearney, Director
Michael Faerm, SVP, MBA
Theodore Witek, SVP, MBA
William Waltrip, Director

Stock Performance

Theravance Performance Indicators